-
Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22
•
On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for HLX22, a monoclonal antibody targeting HER2, for the treatment of gastric cancer (GC). This designation marks a significant milestone in the development of…
-
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
•
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps. Transaction…
-
Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
•
On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404) announced that its subsidiary, Huasheng Pharmaceutical, has signed a technology transfer contract with Panlong Pharmaceutical. The agreement involves the transfer of technology for “Glucosamine Sulfate Capsules” from Huasheng to Panlong, with a total transfer fee…
-
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
•
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS: RHHBY) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. This partnership leverages Oxford BioTherapeutics’ innovative discovery platform to identify and validate new targets for cancer therapies. OGAP-Verify Discovery PlatformOxford BioTherapeutics’ recently…
-
Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment
•
On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class 1 new drug, the PI3Kα inhibitor JYP0035 capsule, received clinical trial approval from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of targeted therapies for breast cancer patients…
-
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
•
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for generic quality and consistency evaluation (GQCE). This initiative is part of the ongoing efforts to ensure the quality and consistency of generic drugs in the market. New AdditionsThe latest batch includes 33 new drugs and…
-
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
•
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue of USD 630.2 million, marking a 25% year-on-year decline. The oncology/immune business segment reported USD 363.4 million, a decrease of 31% compared to the previous year. Oncology Product PerformanceDespite the overall decline, oncology product sales…
-
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
•
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic global licensing agreement for BDTX-4933 on March 19, 2025. This collaboration aims to advance the development of BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Drug ProfileBDTX-4933 is uniquely designed by Black Diamond to…
